Tectonic Therapeutic (NASDAQ:TECX) Shares Down 8.4% - What's Next?

Key Points

• Tectonic Therapeutic shares fell 8.4% to about $32.64 in Monday midday trading, with volume down 72% from the average session level.
• Analyst sentiment remains broadly positive but mixed: the stock has a consensus “Moderate Buy” rating and a $77.80 price target, despite Wells Fargo lowering its target to $93 and some firms maintaining sell-related ratings.
• The company beat quarterly earnings expectations, reporting a loss of $1.18 per share versus the anticipated $1.35 loss. Institutional investors own 62.63% of the stock, while the company is expected to post a full-year loss of $5.25 per share.

Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report)'s share price traded down 8.4% on Monday . The company traded as low as $33.26 and last traded at $32.6380. Approximately 74,839 shares were traded during mid-day trading, a decline of 72% from the average session volume of 264,711 shares. The stock had previously closed at $35.62.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Tectonic Therapeutic in a research note on Friday, July 17th. Wells Fargo & Company decreased their price objective on Tectonic Therapeutic from $101.00 to $93.00 and set an "overweight" rating for the company in a research note on Friday, August 7th. Zacks Research upgraded Tectonic Therapeutic from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 18th. Raymond James Financial raised Tectonic Therapeutic from an "outperform" rating to a "strong-buy" rating and increased their target price for the company from $76.00 to $81.00 in a research note on Tuesday, May 26th. Finally, Wall Street Zen upgraded Tectonic Therapeutic from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.80.

Tectonic Therapeutic Stock Down 13.0%

The company has a market capitalization of $606.05 million, a P/E ratio of -6.78 and a beta of 3.28. The firm has a fifty day simple moving average of $33.16 and a 200-day simple moving average of $30.08.

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.18) earnings per share for the quarter, beating the consensus estimate of ($1.35) by $0.17. On average, sell-side analysts predict that Tectonic Therapeutic, Inc. will post -5.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of hedge funds and other institutional investors have recently made changes to their positions in TECX. Braidwell LP lifted its position in Tectonic Therapeutic by 25.9% in the 4th quarter. Braidwell LP now owns 927,524 shares of the company's stock valued at $19,348,000 after acquiring an additional 190,657 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in shares of Tectonic Therapeutic by 803.4% during the 4th quarter. Baker BROS. Advisors LP now owns 903,400 shares of the company's stock worth $18,845,000 after acquiring an additional 803,400 shares during the period. BlackRock Inc. acquired a new stake in Tectonic Therapeutic in the 2nd quarter worth about $29,652,000. First Light Asset Management LLC acquired a new stake in Tectonic Therapeutic in the 1st quarter worth about $20,022,000. Finally, 5AM Venture Management LLC boosted its holdings in Tectonic Therapeutic by 18.6% in the 4th quarter. 5AM Venture Management LLC now owns 606,660 shares of the company's stock valued at $12,655,000 after purchasing an additional 95,000 shares during the period. 62.63% of the stock is currently owned by institutional investors and hedge funds.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source